Skip to main content

Table 5 Safety on varicella vaccination

From: Varicella infections in patients with end stage renal disease: a systematic review

Reference No of patient studied Complications of vaccine Main conclusions Study quality
Crespo JF, et al. (2002) [16] -17 seronegative patients completed vaccination protocol. -No secondary effect of vaccination detected.
-None of the subsequently seroconverted patients who received kidney transplant presented with VZV disease (up to 18 months post renal transplant).
-Systematic vaccination prior to transplantation could prevent severe varicella. Level 2
Scanlon-Kohlroser CA,et al. (2002) [28] -A single case of 51yo woman at 6 months post-renal transplant developed a mild rash.
-She had daily household contact with 15-month old twins vaccinated 40 days ago.
-Characteristic popular and vesicular rash over the face, trunk, extremities. No dissemination. Confirmed with positive VZV IgG 2 weeks later. -Transmission from those vaccinated to susceptible individuals are rare and typically occurs only if these patients develop a rash.
- Contact cases develop a subclinical infection or mild illness; suggesting vaccine virus remains attenuated when vaccinated.
Level 3
Geel AL, et al. (2006) [17] -11 seronegative patients have been vaccinated with two doses VZV vaccine. - No side effects, no fever, or skin lesions among all vaccinated patients. -Vaccination should be performed in this group of patients in view of potentially lethal complications of primary varicella infection. Level 2
Kho MML, et al. (2016) [32] -52 seronegative patients given two doses of VZV vaccine. -No severe vaccine-related adverse events were reported.
- One had pain at injection site.
-Two had zoster (3 months and 9 years post vaccination)
-One patient developed mild varicella (18 days post vaccination).
  Level 2